Literature DB >> 893226

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

R N Jones, P C Fuchs, T L Gavan, E H Gerlach, A Barry, C Thornsberry.   

Abstract

The in vitro activity of Compound BL-S786 was compared with that of cephalothin against 5,762 clinical isolates by the microdilution broth method. BL-S786 demonstrated a broader spectrum and a significantly lower MIC against the Enterobacteriaceae. Although greater susceptibility to BL-S786 than to cephalothin was exhibited by Serratia marcescens, Proteus morganii and Proteus vulgaris, these three species were generally resistant to both drugs. By contrast, the staphylococci were significantly more susceptible to cephalothin than to BL-S786. Resistance to both drugs was demonstrated by Pseudomonas aeruginosa and other pseudomonads, enterococci and Bacteroides fragilis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 893226     DOI: 10.7164/antibiotics.30.576

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Authors:  P Actor; J V Uri; I Zajac; J R Guarini; L Phillips; D H Pitkin; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

Review 2.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

3.  Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia.

Authors:  R J Wallace; R R Martin; S B Greenberg
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.

Authors:  R N Jones; A L Barry; P C Fuchs; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.

Authors:  S Shadomy; G Wagner; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

6.  BL-S786 (ceforanide), a new parenteral cephalosporin: in vitro studies.

Authors:  S S Weaver; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  In vitro activity and beta-lactamase stability of BL-S786 compared with those of other cephalosporins.

Authors:  N Aswapokee; P Aswapokee; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

10.  Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial.

Authors:  R J Wallace; R R Martin; F J Quinones; S B Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.